Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes

NCT ID: NCT05153070

Last Updated: 2025-06-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-21
• Study Completion Date: 2028-04-21

Brief Summary

Type 1 diabetes (T1D) is caused by the destruction of insulin-producing cells by effector T cells (Teffs), due to a deficiency of regulatory T cells (Tregs).

Ciclosporin effectively blocks the Teffs and controls diabetes, but cannot be considered as a long-term treatment. Low-dose interleukin-2 (ld IL-2) activates and expands Tregs in humans.

Hence, Ld IL-2 in patients in whom the autoimmune process was blocked early by a short treatment (2 months) of cyclosporine should restore immune homeostasis and maintain some insulin production over the long term.

Detailed Description

Primary Objective :

Tregs' response profile, after 4 administrations of 1MIU/day of IL-2 (Day 63-66) in patients with recently diagnosed type 1 diabetes who have been treated with ciclosporin for 2 months.

Primary assessment criterion:

Change in Tregs values at D67 compared to D63 (post-ciclosporin values)

Secondary objectives and secondary assessment criteria:

• Change in residual insulin secretion

• AUC plasma C-peptide concentration after a mixed meal tolerance test at Month 6 (Day 179), Month 12 (Day 361) and after treatment discontinuation at Month 18 (Day 536) and Month 24 (Day 719) compared to baseline;
• Insulin requirement, HbA1c dosage and IDAA1c score at Month 3 (Day 88), Month 6 (Day 179), Month 9 (Day 270), Month 12 (Day 361) and after treatment discontinuation at Month 18 (Day 536) and Month 24 (Day 719) compared to baseline
• Change in Tregs values at Month 3 (Day 88), Month 6 (Day 179), Month 9 (Day 270), Month 12 (Day 361) and after treatment discontinuation at Month 18 (Day 536) and Month 24 (Day 719) compared to baseline and post-ciclosporin values (Day 63)
• Ciclosporin and ILT-101/placebo compliance
• Tolerance

Experimental design:

This is a monocentric, randomized, placebo controlled, double-blind trial in parallel-groups, evaluating a treatment by cyclosporine 7mg/kg/day during 2 months followed by ILT-101/placebo, 1 MIU daily for 5 days and 1 MIU every week, during 10 months.

Population involved:

Male or female, aged between 16 and 35 years, with recent diagnosis of type 1 diabetes (< 3 months).

Number of subjects: 24 Inclusion period: 12 months Duration of patient participation: 24 months (treatment period: 12 months, follow-up period: 12months) Total duration of the study: 37 months

Conditions

Type 1 Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Ciclosporin/ILT-101

Ciclosporin during 2 months (for all patients) followed by ILT-101 during 10 months

Group Type: EXPERIMENTAL

Cyclosporin

Intervention Type: DRUG

• Ciclosporin: 5mg/kg, twice a day, oral, between Day 1 and Day 60

ILT101

Intervention Type: DRUG

• ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.

Ciclosporin/placebo

Ciclosporin during 2 months (for all patients) followed by placebo during 10 months

Group Type: PLACEBO_COMPARATOR

Cyclosporin

Intervention Type: DRUG

• Ciclosporin: 5mg/kg, twice a day, oral, between Day 1 and Day 60

Placebo

Intervention Type: DRUG

• Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.

Interventions

Cyclosporin

• Ciclosporin: 5mg/kg, twice a day, oral, between Day 1 and Day 60

Intervention Type: DRUG

ILT101

• ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.

Intervention Type: DRUG

Placebo

• Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• • Age at inclusion between ≥ 16 years old (Tanner 5 pubertal stage) and ≤ 45 years old

• Type 1 diabetes according to ADA criteria, with at least 1 positive autoantibody among the following: anti-islet, anti-GAD, anti-IA2, anti-ZnT8 and anti-insulin.
• Diagnosis ≤ 3 months
• No acid ketosis
• No weight loss > 10% OR with fasting C-peptide ≥ 0.1 nmol/L (after a period of ≥ 15 days following the initiation of insulin therapy
• Absence of clinically significant biological abnormalities on hematological, biochemical, hepatic, renal and thyroid tests.
• No documented history of heart disease, no family history of sudden death, AND normal ECG.
• Effective contraception in men and women of childbearing potential > 2 weeks prior to first administration of the investigational drug and throughout the treatment period (if sexually active). Specifically for women of childbearing age and sexually active, they must use an effective contraceptive method (Pearl Index < 1). The following methods are acceptable: oral hormonal contraceptives, injectable, or implanted (with the exception of oral minipills: i.e. low doses of gestagens which are not acceptable (lynestrenol and norestisteron), intrauterine contraceptives (e.g. progestin-release systems)),
• Free, informed and written consent, signed by the patient and the investigator, prior to any examination required by the trial.

If the patient is a minor, the signatures of both parents and of the child will be collected (or the legal representative if only one parent is alive).

Exclusion Criteria

• Known contraindications to IL2 treatment:

• Hypersensitivity to the active substance or to one of the excipients.
• Signs of active infection requiring antibiotics
• Documented history of clinical autoimmune disease
• Oxygen saturation ≤ 90%
• Existence of a serious dysfunction in a vital organ
• History of organ allograft,
• Known contraindications to treatment with cyclosporine
• Presence of unauthorized treatment, i.e. cytotoxic drugs, products known for their impact on blood glucose levels or for their interactions with the treatments under trial
• Patients who have received anti-diabetic treatment other than insulin for more than 3 consecutive months.
• Anti-thyroperoxidase positive and abnormal TSH and T4 at inclusion
• Anti-transglutaminase positive at inclusion
• EBV viral load > 2000 IU/ml
• CMV viral load > 400 IU/ml
• HBV, HCV or HIV infection
• Lymphopenia ≤ 1000/ mm3
• Presence or history of cancer that has been cured for less than five years, except in situ cervical or basal cell carcinoma in early stage management,
• Participation in other intervention research involving humans < 3 months,
• Pregnant or breastfeeding women
• Lack of social security affiliation (as a beneficiary or assignee)
• Vaccination with live attenuated virus during the last 4 weeks before the start of the experimental treatment and during the entire treatment phase.
• Patient with active SARS-CoV-2 infection
• Patient with chronic respiratory disease
• Subject under legal protection (such as tutorship, curatorship, or judicial safeguard)
• Subject hospitalized without consent, unable to express consent or deprived of liberty

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Iltoo Pharma

INDUSTRY

Sponsor Role: collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Klatzmann, MD, Ph.D

Role: STUDY_DIRECTOR

APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS

Agnès Hartmann, MD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS

Locations

Lorenzon Roberta

Paris, , France

Site Status: RECRUITING

Countries

France

Central Contacts

David Klatzmann, MD, Ph.D

Role: CONTACT

david.klatzmann@sorbonne-universite.fr

01 42 17 74 61 ext. +33

Roberta Lorenzon, MD

Role: CONTACT

roberta.lorenzon@sorbonne-universite.fr

01 42 17 65 16 ext. +33

Facility Contacts

Roberta Lorenzon, MD

Role: primary

roberta.lorenzon@sorbonne-universite.fr

Other Identifiers

P120142

Identifier Type: -

Identifier Source: org_study_id